🔗 Share this article The Global Health Body Issues Warning Over Critical Shortage of Weight-Loss Injections Fewer than a tenth of patients that would benefit from weight-loss injections like Wegovy can access them, warns the global health agency as it publishes its initial recommendations on the therapies. Given in excess of 1,000,000,000 people worldwide currently obese, it is urging more widespread and fairer access to GLP-1 medication. According to forecasts, over two billion will be obese by 2030 without intervention. "The latest guidelines recognises that obesity is a long-term condition that can be addressed with thorough and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and logistical bottlenecks are significant barriers to universal availability to the treatments that can assist patients in reducing significant body mass, says the body. Weight-Loss Drug Scarcity Even in the current most favorable case, the production of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of those who need them, according to the WHO. The advice urges countries and companies to increase availability, via approaches like patent sharing. A patent on semaglutide – the primary component of a leading brand – is scheduled to end in a number of nations in 2026. How Obesity Injections Operate These medications mimick a biological compound to delay gastric emptying, reduce hunger and boost feelings of fullness so users consume fewer calories. People commonly start to lose weight within a few weeks of starting on the once-weekly jabs. Studies suggests patients may see weight return a year later of stopping the treatment, when their usual appetite return. Being above a healthy weight raises your chance for developing medical conditions, such as type 2 diabetes, heart disease, stroke, and some cancers. Obesity affects people in all nations and was responsible for millions of deaths worldwide in 2024, according to the health agency.
Fewer than a tenth of patients that would benefit from weight-loss injections like Wegovy can access them, warns the global health agency as it publishes its initial recommendations on the therapies. Given in excess of 1,000,000,000 people worldwide currently obese, it is urging more widespread and fairer access to GLP-1 medication. According to forecasts, over two billion will be obese by 2030 without intervention. "The latest guidelines recognises that obesity is a long-term condition that can be addressed with thorough and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus. High costs, limited production capacity, and logistical bottlenecks are significant barriers to universal availability to the treatments that can assist patients in reducing significant body mass, says the body. Weight-Loss Drug Scarcity Even in the current most favorable case, the production of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of those who need them, according to the WHO. The advice urges countries and companies to increase availability, via approaches like patent sharing. A patent on semaglutide – the primary component of a leading brand – is scheduled to end in a number of nations in 2026. How Obesity Injections Operate These medications mimick a biological compound to delay gastric emptying, reduce hunger and boost feelings of fullness so users consume fewer calories. People commonly start to lose weight within a few weeks of starting on the once-weekly jabs. Studies suggests patients may see weight return a year later of stopping the treatment, when their usual appetite return. Being above a healthy weight raises your chance for developing medical conditions, such as type 2 diabetes, heart disease, stroke, and some cancers. Obesity affects people in all nations and was responsible for millions of deaths worldwide in 2024, according to the health agency.